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Edited by Jesus AvilaAbstract D9-tetrahydrocannabinol (D9-THC) and cannabidiol
(CBD) are two major constituents of Cannabis sativa. D9-THC
modulates sleep, but no clear evidence on the role of CBD is
available. In order to determine the eﬀects of CBD on sleep, it
was administered intracerebroventricular (icv) in a dose of
10 lg/5 ll at the beginning of either the lights-on or the lights-
oﬀ period. We found that CBD administered during the lights-
on period increased wakefulness (W) and decreased rapid eye
movement sleep (REMS). No changes on sleep were observed
during the dark phase. Icv injections of CBD (10 lg/5 ll) in-
duced an enhancement of c-Fos expression in waking-related
brain areas such as hypothalamus and dorsal raphe nucleus
(DRD). Microdialysis in unanesthetized rats was carried out to
characterize the eﬀects of icv administration of CBD (10 lg/
5 ll) on extracellular levels of dopamine (DA) within the nucleus
accumbens. CBD induced an increase in DA release. Finally, in
order to test if the waking properties of CBD could be blocked by
the sleep-inducing endocannabinoid anandamide (ANA), animals
received ANA (10 lg/2.5 ll, icv) followed 15 min later by CBD
(10 lg/2.5 ll). Results showed that the waking properties of
CBD were not blocked by ANA. In conclusion, we found that
CBD modulates waking via activation of neurons in the hypo-
thalamus and DRD. Both regions are apparently involved in
the generation of alertness. Also, CBD increases DA levels as
measured by microdialysis and HPLC procedures. Since CBD
induces alertness, it might be of therapeutic value in sleep disor-
ders such as excessive somnolence.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cannabis sativa preparations (marijuana, hashish, bhang
and others) are the most widely used illicit drugs in the world
[1]. D9-tetrahydrocannabinol (D9-THC) and cannabidiol
(CBD) are two major constituents of marijuana [2,3]. D9-
THC is a psychoactive compound and produces stereotypical
behaviours [4]. The cannabinoid receptor CB1 is thought to
be responsible for the majority of the eﬀects in the central
nervous system (CNS) elicited by D9-THC, since it binds and
activates this receptor [5].
CBD does not bind to CB1 and is not psychoactive. The
chemistry of CBD has been well explored [6–8] and some of
its CNS pharmacological properties have been examined [9],
including its anticonvulsant, sedative and anxiolytic eﬀects
[10–12]. For instance, Guimaraes and co-workers found that
CBD (2.5–10 mg/kg) induced an anxiolytic-like eﬀect evalu-
ated by the elevated plus maze assay whereas Lastres-Becker
et al. have reported that CBD displays neuroprotection against
6-hydroxydopamine toxicity [13,14].
While it is well established that D9-THC increases sleep [15–
17], contradictory results on the eﬀects of CBD have been pub-
lished. For example, Monti et al. reported a reduction of sleep
by systemic administration of CBD [18]. On the other hand,
Carlini and Cunha showed that CBD improved sleep in insom-
niacs [19]. Recently, Nicholson et al. found that 15 mg of CBD
administered to young adults increased wakefulness (W) dur-
ing sleeping time [20].
The mechanism of sleep modulation by CBD remains un-
clear. Presumably, it could include changes in dopamine
(DA) levels, as the nigrostriatal dopaminergic system has been
pointed out as an important element in the manifestations of
the cannabinoid-induced behavioural alterations. Indeed the
extracellular levels of DA are enhanced following D9-THC
administration [21–23]. The eﬀects of CBD on catecholamine
levels are not known.
As indicated above although CBD does not bind to the CB1
cannabinoid receptor [24,25], it elicits numerous CNS-associ-
ated eﬀects, including the sleep–wake cycle. In view of the
divergent eﬀects reported so far we decided to reinvestigate this
phenomenon using techniques diﬀerent from those reported
previously. First we determined the pharmacological eﬀects
of unilateral intracerebroventricular (icv) administration of
CBD on sleep in rats. Then we analysed the eﬀects of CBD
on c-Fos immunoreactivity followed by measurement of DA
extracellular levels collected from nucleus accumbens (AcbC)
using microdialysis and HPLC. Finally, we looked into theblished by Elsevier B.V. All rights reserved.
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induced by CBD as we have previously reported that the endo-
cannabinoid ANA increases sleep [26–28].2. Materials and methods
2.1. Animals
Male wistar rats (n = 50; 250–300 g) were housed at constant tem-
perature (21 ± 1 C) and under a controlled light–dark cycle (lights-
on: 07:00–19:00 h). Food and water were provided ad libitum.
2.2. Surgery, EEG/EMG electrodes and icv cannulae
Under deep anesthesia (acepromazine [0.75 mg/kg], xylazine [2.5 mg/
kg], and ketamine [22 mg/kg, ip]) all animals (n = 12) were implanted
for sleep studies with EEG and EMG electrodes and a cannula (23
gauge) was placed into one lateral ventricle (A = 0.8; L = 1.6;
H = 3.6; [29]). All electrodes and cannulae were placed and secured
onto the skull using dental cement. These procedures have been re-
ported previously by our group [26,27]. After surgeries, all animals
were placed into the sleep-recording chambers for habituation.
2.3. Surgery, microdialysis guide-cannulae
A diﬀerent group of rats was used for microdialysis study (n = 14). A
guide-cannula (IC guide. BioAnalytical Systems [BAS], West Lafay-
ette, IN, USA) was placed stereotaxically into the Accumbens nucleus,
core (AcbC; target coordinates: A = +1.2; L = 2.0;H = 7.0; [29]). The
guide-cannulae was then ﬁxed onto the skull with a thin layer of dental
cement. After surgery, each animal was placed into the Microdialysis
Bowl to habituate to the experimental conditions. All animals were
allowed to recover for at least 7 days after all surgeries.
2.4. Administrations
CBD was prepared in our lab as previously reported [25] and ANA
was purchased from Sigma (USA). All compounds were dissolved in
vehicle (PEG/saline; 5:95 v/v). In order to test the eﬀects of CBD on
the sleep during the lights-on or lights-oﬀ period, rats were injected
icv either with vehicle or CBD (10 lg/5 ll) at 07:00 h or at 19:00 h.
For the combination experiment in which we examined the eﬀect of
ANA on the eﬀects produced by CBD, additional groups of rats were
used. Control group (n = 6) received vehicle. The following groups re-
ceived either ANA (10 lg/5 ll; n = 6) or CBD (10 lg/5 ll; n = 6). The
last group (n = 6) received ANA (10 lg/2.5 ll) and 15 min later CBD
(10 lg/2.5 ll). Injections were done at 07:00 h.
All icv administrations were done slowly over 1 ll/min with the
injector left in the target for an additional 15 s to ensure extrusion from
the tip and to minimize distribution of treatments upwards on the can-
nulae. After all injections, the cannula was withdrawn and the stylet
was replaced. Right after microinjections, animals were attached to
the sleep-recording system.
2.5. Analyses of sleep recordings
The EEG/EMG data recordings were scored manually and epochs
for W, slow wave sleep (SWS) and rapid eye movement sleep (REMS)
were measured as described previously [26,27]. The analysis was re-
stricted to 4 h after injections since pharmacokinetic studies show that
CBD is rapidly absorbed. On iv administration, CBD has a terminal
half life of 9 h [30].
2.6. Microdialysis sampling procedures
One week after surgery and a day before the experiment, a microdi-
alysis probe (1 mm of length; polyacrylonitrile, MWCO = 30000 Da;
340 lm OD; BAS) was inserted through the guide cannula into the tar-
get structure at 7:00 h and the tissue were allowed to stabilize for 24 h.
During this period artiﬁcial cerebrospinal ﬂuid (ACSF, composition:
NaCl (147 mM), KCl (3 mM), CaCl (1.2 mM), MgCl (1.0 mM), pH
7.2) was perfused through a FEP Teﬂon Tubing (0.65 mm
OD · 0.12 mm ID) continuously using a 2.5 ml gastight syringe. All
procedures have been reported previously [28]. A syringe pump
(CMA/100) controlled the speed of perfusion of the ACSF (ﬂow rate:
1 ll/min). Since we had found changes in sleep after CBD injectionduring the lights-on period, we administered the treatments at the
beginning of the lights-on period and right after this, samples were col-
lected during 4 h.
2.7. Analysis of DA
Immediately after collection samples were injected into a HPLC
(BAS) for DA analysis. Brieﬂy, the mobile phase consisted of mono-
chloroacetic acid (0.1 M), sodium octylsulfate (223 mM) and disodium
ethylenediaminetetraacetate dihydrate (0.5 mM) with a ﬂow rate of
80 ll/min. Separation was achieved by a BAS microbore column (bio-
phase octyl, 5 lm, 250 · 4.6 mm; BAS). Electrochemical detection was
performed via BAS 4C detector. Chromatographic data was recorded
on a PC computer and peak heights of DA in microdialysis samples
were compared to standards. DA peaks were initially identiﬁed by run-
ning samples (also 10 ll) that contained diﬀerent concentrations of
DA. All details of this procedure were reported by our group previ-
ously [31].
2.8. Immunohistochemical study
At the end of the experiments, animals received either vehicle or CBD
(10 lg/5 ll, icv). The treatments were administered at the beginning of
the lights-on period and the animals were sacriﬁced 1-h post-injection
with a lethal dose of pentobarbital. They were perfused transcardially
with 0.9% saline solution followed by paraformaldehyde and then fol-
lowed by 20% sucrose–0.1 M PBS for 48 h. The brains were cut (frozen
sections, 30 lm, coronal) and collected in 1:5 serial orders. Immunohis-
tochemistry for c-Fos was done as described in detail by our group [32].
In addition to the c-Fos study, sections were lightly counterstained with
Neutral Red to allow better visualization of the cannula track. All stud-
ies were conducted in accordance with the principles and procedures
described in the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
2.9. Statistical analysis
The data are presented as means and standard errors. Student t test
was used to compare control and CBD groups in the ﬁrst two experi-
ments and a P-value < 0.05 was considered statistically signiﬁcant. In
the following experiments, statistical analysis was carried out by one-
way analysis of variance (ANOVA). When a signiﬁcant P-value was
found among the groups, the post-hoc Sheﬀe´ test was used to asses dif-
ferences in two group comparisons (STATVIEW).3. Results
3.1. Eﬀects of CBD in sleep
We injected CBD (n = 6; 10 lg/5 ll) or vehicle (n = 6) during
the normal sleeping period (07:00–19:00 h, lights-on) of rats.
CBD markedly increased the total time spent in W
(DF = 10; t = 2.267; P < 0.05; Fig. 1A). We also found that
CBD induced a signiﬁcant diminution of REM sleep
(DF = 10; t = 3.756; P < 0.05), whereas no statistical changes
were observed in SWS. As shown in Fig. 1B, CBD enhanced
W about 1 h after drug administration (DF = 10; t = 2.507;
P < 0.05) as well as during the last hour (DF = 10;
t = 3.808; P < 0.005). The eﬀects of CBD on SWS hour by
hour are displayed in Fig. 1C. We found that CBD also mod-
iﬁed this sleep stage during the second hour (DF = 10;
t = 2.672; P < 0.05) and the fourth hour (DF = 10;
t = 2.126; P < 0.05). Analysis of REMS hour by hour after
administration of CBD is shown in Fig. 1D. CBD inhibited
the time spent in REMS across 4 h of sleep recordings; how-
ever, statistical diﬀerence was found only at the fourth hour
(DF = 10; t = 3.709; P < 0.005).
On the other hand, CBD injected (n = 6) at the beginning of
the lights-oﬀ period did not modify the total time of W
(DF = 10; t = 0.546; P > 0.59), SWS (DF = 10; t = 0.212;
P > 0.83) and REMS (DF = 10; t = 1.25; P > 0.23) compared
Fig. 1. The icv administrations of either vehicle or CBD (10 lg/5 ll)
were done at the start of the lights-on period, and right after injections,
the sleep was recorded during 4 h. The eﬀects of CBD on the total time
of W, SWS and REMS are shown in panel A. Hour-by-hour group
averages of W (B); SWS (C) and REMS (D) after icv injection of either
vehicle or CBD (means ± S.E.M. of total time of recording (%); * vs
control, P < 0.05).
Fig. 2. The icv injection of CBD (10 lg/5 ll) at the start of the lights-
oﬀ period did not modify the total time (4 h of sleep recordings) of W,
SWS and REMS as shown in panel A. The time course of W (B), SWS
(C) and REMS (D) show no signiﬁcant statistical diﬀerences (means ±
S.E.M. of total time of recording [%]; * vs control, P < 0.05).
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of the pharmacodynamic eﬀects of CBD on sleep stages are
shown in Fig. 2B–D, respectively, showing no signiﬁcant
changes.
3.2. c-Fos expression after CBD injection
Treatment with CBD (10 lg/5 ll) consistently increased the
pattern of neuronal activation marked by Fos expression inbrain regions, such as lateral hypothalamus and dorsal raphe
nucleus (DRD). Some of the most striking changes in c-Fos
expression were found within speciﬁc hypothalamic areas
implicated in the alertness control (Fig. 3). Neurons of hypo-
thalamus are active during W [33], and because all animals
were mainly awake, it was not surprising that c-Fos-immuno-
reactivity hypothalamic neurons were activated in rats that re-
ceived CBD. Following unilateral icv injection of CBD (10 lg/
5 ll), labelled c-Fos cells were observed in hypothalamic areas,
Fig. 4. Immunohistochemical staining for c-Fos in the DRD of the
rat. Panel A shows the expression of c-Fos from a control rat (vehicle).
Panel B shows the immunostaining obtained from a CBD-treated
animal (10 lg/5 ll icv). The treatments were administered at the start
of the lights-on period and the animals were sacriﬁced 1 h post-
injection. Abbreviations: Aq, aqueduct (Sylvius); DRD, dorsal raphe
nucleus, dorsal part. Scale bar: 100 lm.
Fig. 3. Immunohistochemical staining for c-Fos in the hypothalamus
of the rat. Panel A shows the expression of c-Fos from a control rat
(vehicle). Panel B shows the c-Fos immunostaining obtained from a
CBD-treated animal (10 lg/5 ll icv). The treatments were administered
at the beginning of the lights-on period and the animals were sacriﬁced
1 h post-injection. Abbreviations: 3V, 3rd ventricle. Scale bar: 100 lm.
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hypothalamic nucleus (DMH). Therefore, we found that CBD
induced an increase in c-FOS expression in MPO compared
with the control group (Fig. 3).
On the other hand, in the brainstem, only neurons in the
DRD showed signiﬁcant labelling pattern of Fos-immunoreac-
tivity after treatment with CBD (10 lg/5 ll). Representative
examples of c-Fos immunoreactivity are shown in Fig. 4. All
icv injections were made unilaterally. No diﬀerences among
control and CBD group were evident in other brainstem nu-
clei, including the pedunculopontino, laterodorsal tegmental
nuclei and locus coeruleus.
3.3. Eﬀects of CBD on DA levels
Fig. 5 identiﬁes the location of the cannula in the AcbC nu-
cleus from where the DA was measured. The variation in
location of the cannula across the rats was as follows: ante-
rior–posterior was Bregma +1.70 mm to Bregma 0.70 mm;
lateral was 1.5–2.0 mm and dorsal–ventral was 7.5–7.9 mm.
Results showed that levels of noradrenaline (NA) were sig-
niﬁcant increased compared with a control group (n = 7) in
the ﬁrst hour (DF = 12; t = 2.844; P < 0.01; Fig. 6A) and
in the second hour (DF = 12; t = 2.137; P < 0.005; Fig. 6A)
post-injection of CBD (10 lg/5 ll; n = 7). After injection of
CBD, epinephrine levels were also enhanced compared withlevels in control rats in the ﬁrst hour (DF = 12; t = 12.006;
P < 0.0001; Fig. 6B) as well as in the second hour (DF = 12;
t = 5.387; P < 0.0002; Fig. 6B).
CBD also induced enhancement in DA levels one hour after
injection (DF = 12; t = 3.290; P < 0.05; Fig. 6C) and this ef-
fect remained in the second hour (DF = 12; t = 2.149;
P < 0.05; Fig. 6C) whereas 3,4-dihydroxy-L-phenylalanine (L-
DOPA) extracellular levels decreased one hour after injection
of CBD (DF = 12; t = 2.799; P < 0.01; Fig. 6D) as well as in
the second hour (DF = 12; t = 2.281; P < 0.05; Fig. 6D).
Lastly, serotonin (5-HT) was increased 1 h post-CBD
administration (DF = 12; t = 16.741; P < 0.0001; Fig. 6E)
as well as 2 h post-CBD injection (DF = 12; t = 19.058;
P < 0.0001; Fig. 6E). Levels of 5-hydroxy-indoleacetic acid
(5-HIAA) were decreased 1 h after administration of CBD
(DF = 12; t = 6.074; P < 0.0001; Fig. 6F). Fig. 6G shows that
no eﬀect was found on extracellular levels of homovanillic acid
(HVA) after CBD injection.
3.4. Eﬀects of the sleep-inducing endocannabinoid ANA on the
waking-inducing properties of CBD
As found in our previous experiments [26–28], ANA sub-
stantially decreased waking and increased total sleep time.
Administration of ANA 15 min before CBD did not block
either the wake-inducing eﬀect caused by CBD or the diminu-
tion in SWS (F = 22.472; DF = 20; P < 0.0001; Fig. 7). Despite
the evident sleep-inducing eﬀect caused by ANA, the enhance-
ment in W as well as the diminution in total sleep time was still
present with the administration of CBD after 4 h of sleep
recordings.
Fig. 5. Histological veriﬁcation of the microdialysis probe position.
Panel A shows the schematic representation of the localization of the
microdialysis probe in the AcbC represented by the black bar.
Stereotaxic coordinates, drawings and abbreviations were taken from
the Paxinos and Watson [29] atlas. Microphotography of the track of
the microdialysis probe in the AcbC is shown in Panel B. Abbrevi-
ations: AcbC: nucleus accumbens, core; CPu, caudate putamen. Scale
bar: 100 lm.
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The experiments described in this report were designed to
throw light on the pharmacological eﬀects of CBD on sleep
patterns of rats. Several physiological parameters were consid-
ered, such as the eﬀects of CBD on the sleep–wake cycle, DA
formation, c-Fos expression and interaction with ANA on
sleep.
Under our conditions, icv administrations of CBD (10 lg/
5 ll) during the lights-on period increased waking, but de-
creased REM sleep in rats (Fig. 1A). The alertness was ob-
served already after the ﬁrst hour post-injection (Fig. 1B).
Injection of CBD during the lights-oﬀ period did not modify
the sleep wake-cycle (Fig. 2A).
We also found that CBD increased c-Fos expression as re-
ported by others [34]. The induction of Fos protein encoded
by the immediate early gene c-fos, is often used as a marker
of neural activation. The present results demonstrate that
CBD induced changes in the Fos-immunoreactive cells in
some waking-related brain areas, including hypothalamic nu-
clei (Fig. 3) as well as DRD (Fig. 4). The hypothalamic nuclei
have been associated with waking [35–37]. For example, theDMH contains neurons that are speciﬁcally active during
W [38].
As shown in Fig. 4, a population of neurons in the DRD
exhibited enhanced c-Fos-immunoreactivity after CBD micro-
injection compared to controls. The DRD ﬁring activity is
higher in the waking state and decreases during sleep, being
virtually absent in REM sleep [39–41]. These ﬁndings empha-
size the hypothesis that one of the neurochemical mechanisms
underlying the vigilance-promoting action of CBD could be re-
lated to its ability to enhance the serotoninergic transmission.
It has been reported recently that CBD displays 5-HT agonists
[42], suggesting with this a potential activation of 5-HT recep-
tors via CBD.
Catecholamine levels collected from AcbC were monitored
during 4 h post-injection of CBD (10 lg/5 ll, icv). We found
an increase in the levels of NA, epinephrine, DA and 5-HT
(Fig. 6A–C and E, respectively). On the other hand, the extra-
cellular levels of L-DOPA and 5-HIAA were decreased
(Fig. 6D and F, respectively).
The enhancement in DA levels in our study is supported by
the ﬁndings of McPartland and Russo [43]. We believe that
waking induced by CBD may be associated with the increase
in the release of DA since it is known that lesions of DA cell
groups induce a reduction in arousal in rats [44] as well as in
Parkinson’s disease patients [45,46]. The regulation of the
sleep–wake cycle in mammals’ includes neuromodulators such
as DA; for instance, administration of DA receptor agonists
[47] or DA uptake inhibitors [48] induces an increase in wak-
ing. The role of DA on alertness has been also tested in
invertebrates including Drosophila [49]. On the other hand,
the relative changes in the concentrations of DA have been
demonstrated by Lena et al. [50]. Using the microdialysis
technique, the authors reported that extracellular levels of
DA were elevated during waking [50]. Finally, the electro-
physiological activity of DA neurons is higher during alert-
ness as suggested by Lu et al. [51]. The evidence mentioned
above indicates that indeed DA plays an active role in the
promotion of waking [52]. In our study, we found that
CBD increased W and enhanced the extracellular levels of
DA collected from AcbC, ﬁnding which is supported by
McPartland and Russo [43]. A possible mechanism of this ef-
fect remains to be elicited. However, we cannot rule out some
hypothesis, including that CBD might be acting at diﬀerent
receptors. For instance, it has been suggested that CBD
may bind to the vanilloid receptor [24] or by modulating
Ca2+ inﬂux. Recently, Drysdale et al. reported that CBD ele-
vated intracellular Ca2+ concentrations in hippocampal cul-
tures [53]. Thus, the present results provide scope for
speculation on the role of CBD on the mechanisms of release
of DA.
While AcbC is a good target for DA sampling it may not be
a good option for 5-HT sampling. However data obtained
from microdialysis study suggests that the increase in NA, epi-
nephrine and 5-HT levels could be an additional distant target
for CBD eﬀects.
While D9-THC and CBD cause some similar actions (albeit
possibly based on diﬀerent mechanisms) such as anti-inﬂam-
matory [54] and antiemetic eﬀects [55], here we show a
dichotomy in their eﬀects on sleep patterns. D9-THC in-
creases sleep [15–17], whereas CBD induces an opposite ef-
fect. Nicholson et al. have reported that CBD increases
waking in humans [20].
Fig. 6. Extracellular levels of catecholamines measured in the AcbC during a 4-h period after the administration of either vehicle or cannabidiol (CBD,
10 lg/5 ll icv). Noradrenaline (A), epinephrine (B), dopamine (C), L-DOPA (D), 5-HT (E), 5-HIAA (F) and HVA (G). The treatments were
administered at the beginning of the lights-on period and right after this, samples were collected. Each point represents the means ± S.E.M. of pM
(* vs control, P < 0.05).
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tions. Contrary to D9-THC, it has very little aﬃnity for the
known cannabinoid receptors, CB1 and CB2 [24]. We assume
that the eﬀects of CBD found in our study might be through
action on a receptor not yet described. An alternative explana-
tion involves the fatty acid amide hydrolase (FAAH) (the
intracellular enzyme that catalyzes the hydrolysis of endoge-
nous cannabinoids ligand, ANA [56] and the anorexic lipid
oleoylethanolamide (OEA) [57]). In the last experiment ofour study we hypothesized an enhanced eﬀect of ANA on sleep
following CBD injection. Surprisingly, CBD increased waking
even in presence of ANA. We do believe that CBD might be
inhibiting FAAH; this could lead an increase in endogenous
ANA levels in the brain. However, the use of the URB597 (a
FAAH inhibitor) enhances OEA levels in the brain in higher
rates than ANA as reported by Fegley et al. [58]. In our lab,
we have tested the physiological properties of URB597 as well
as OEA on sleep–wake cycle and have found a signiﬁcant in-
Fig. 7. Eﬀects of icv administrations of either vehicle, cannabidiol
(CBD, 10 lg/5 ll), anandamide (ANA; 10 lg/5 ll), ANA (10 lg/2.5 ll)
and 15 min later CBD (10 lg/2.5 ll; ANA + CBD) on the total time of
W and total sleep time (TST). The treatments were administered at the
beginning of the lights-on period and right after this, sleep was
recorded during 4 h. Each point represents the means ± S.E.M. of total
time of recording (%; * vs control, P < 0.05).
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wise unknown. It is highly possible that CBD inhibits FAAH
activity and this leads to an increase in the levels of OEA,
which facilitates waking.
Our study suggests that CBD induces alertness via activation
of neurons in the hypothalamus and DRD. Additionally, levels
of DA, NA, epinephrine as well as 5-HT were enhanced after
CBD injections. These eﬀects can be induced by a novel cellu-
lar pathway involved in the alertness caused by CBD. It seems
that the enzymatic process involved in the formation of cate-
cholamines might be under the inﬂuence of CBD. Likely the
component enzymes in the pathway could be inhibited or stim-
ulated by CBD. For example, we found that CBD increased
DA but decreased levels of L-DOPA, meaning that the activity
of tyrosine hydroxylase could be under inhibition whereas
DOPA decarboxylase may be stimulated. Complementary
experiments testing the role of CBD on the biosynthesis of cat-
echolamines would provide us a better understanding of the
phenomena.
CBD has been tested lately as a therapeutical agent [14,59–
64]. The present results indicate an additional potential thera-
peutic beneﬁt of this compound such as excessive somnolence.
Early studies have indicated that sleep may be modulated by
cannabinoids [15–17] or cannabis extracts. In most experi-
ments with extracts however the levels of CBD were not mea-
sured. Here we describe the waking properties of CBD. It
might be considered to treat sleep disorders such as excessive
somnolence. This common sleep disturbance is deﬁned as trou-
ble falling asleep or staying asleep. It can cause sleepiness or
fatigue during the day, may aﬀect mood and result in trouble
focusing on tasks. According to National Sleep Foundation re-
sults from the 2005 Sleep in America poll indicate that 60% of
America’s adults who drive or have a license report that, with-
in the past year, they have driven a car or motor vehicle when
feeling drowsy. We now could consider the use of CBD, the
non-psychoactive constituent of C. sativa, to treat sonmolence.
In summary, administration of CBD to rats produced wak-
ing in association with activation of hypothalamic and DRD,
two brain regions implicated in the control of alertness. Extra-cellular levels of NA, epinephrine, DA, and 5-HT were en-
hanced after CBD injections. The wake-inducing properties
of CBD were not blocked by the sleep-inducing endocannabi-
noid ANA. Activation of speciﬁc arousal regions may underlie
the W produced by CBD in people with somnolence. Future
studies will be needed to address the question of whether vanil-
loid receptors, Ca2+ inﬂux or the interactions between CBD
and CB1-signalling pathways contribute to the alertness and
DA release actions of CBD.
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